Results 11 to 20 of about 91,272 (228)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +5 more sources

Pitfall in the high-throughput quantification of whole blood cyclosporin A using liquid chromatography-tandem mass spectrometry [PDF]

, 2005
In a growing number of laboratories the technique of liquid chromatography-tandem mass spectrometry is used for the quantification of cyclosporin A in whole blood, employing cyclosporin D as the internal standard. Cyclosporin A is extensively metabolized
Spöhrer, Ute, Vogeser, Michael
core   +2 more sources

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. [PDF]

, 2016
PurposeTo determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Materials and methodsPatients who were 1 to 30 years of age
Allen, Shelly, DuBois, Steven G, Gustafson, W Clay, Hollinger, Fabienne, Karski, Erin E, Long-Boyle, Janel R, Matthay, Katherine K, Nasholm, Nicole M, Shiboski, Stephen, Vo, Kieuhoa T   +9 more
core   +1 more source

Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology

Pharmaceutics, 2021
Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as ...
Amelia-Naomi Sabo, Sarah Jannier, Guillaume Becker, Jean-Marc Lessinger, Natacha Entz-Werlé, Véronique Kemmel   +5 more
doaj   +1 more source

Long-term efficacy and safety of sirolimus for retinal astrocytic hamartoma associated with tuberous sclerosis complex

Frontiers in Cell and Developmental Biology, 2022
Mammalian target of rapamycin (mTOR) inhibitors (sirolimus or everolimus) have been demonstrated effective in reducing the size of tuberous sclerosis complex (TSC)-associated retinal astrocytic hamartoma (RAH) in short term.
Chen-Xi Zhang, Kai-Feng Xu, Qin Long, Xiao Zhang, Zhi-Kun Yang, Rong-Ping Dai, Zhi-Qiao Zhang   +6 more
doaj   +1 more source

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel [PDF]

, 2020
No biomarker panel is established for prediction of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), a major complication of allogeneic stem cell transplantation (alloSCT).
Blau, Igor W., Bullinger, Lars, Dreger, Peter, Jiang, Sihe, Luft, Thomas, Majer-Lauterbach, Joshua, Müller-Tidow, Carsten, Penack, Olaf, Radujkovic, Aleksandar, Schult, David, Terzer, Tobias   +10 more
core   +3 more sources

Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis

Orphanet Journal of Rare Diseases, 2021
Background Patients with lymphangioleiomyomatosis (LAM) frequently experience pneumothorax. Although sirolimus is the standard therapy for LAM, its effect on pneumothorax is controversial.
Teiko Sakurai, Toru Arai, Masaki Hirose, Kensuke Kojima, Tetsuki Sakamoto, Yoshinobu Matsuda, Chikatoshi Sugimoto, Hyung-Eun Yoon, Yoshikazu Inoue   +8 more
doaj   +1 more source

Enhanced Supersaturation and Oral Absorption of Sirolimus Using an Amorphous Solid Dispersion Based on Eudragit® E

Molecules, 2015
The present study aimed to investigate the effect of Eudragit® E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral ...
Youngseok Cho, Eun-Sol Ha, In-Hwan Baek, Min-Soo Kim, Cheong-Weon Cho, Sung-Joo Hwang   +5 more
doaj   +1 more source

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). [PDF]

, 2018
The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing rapidly due to growing proportion of HPV-related disease and development of new therapeutic agents.
Jung, Kyungsuk, Kang, Hyunseok, Mehra, Ranee   +2 more
core   +2 more sources

Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review

Acta Dermato-Venereologica, 2019
Vascular anomalies (VAs) may be associated with significant morbidity and mortality. The aim of this study was to evaluate the efficacy and safety of sirolimus (rapamycin) in the treatment of children and young adults with complicated VAs.
Shira Sandbank, Vered Molho-Pessach, Adam Farkas, Aviv Barzilai, Shoshana Greenberger   +4 more
doaj   +1 more source